PVLA · Palvella Therapeutics, Inc.

$151.82 +1.85 (+1.23%)

Russell 2000 member Rebalance outlook locked

Market Cap

$2.16B

14.41M

Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-08-12	Canaccord Genuity 46th Annual Growth Conference	Conference
2026-08-04	Earnings conference call (announced in 8-K)	Earnings call
2026-06-09	Goldman Sachs 47th Annual Global Healthcare Conference	Conference
2026-05-07	Earnings conference call (announced in 8-K)	Earnings call
2026-03-31	Earnings conference call (announced in 8-K)	Earnings call
2026-02-24	Palvella Therapeutics Conference Call to Discuss Topline Results from the Phase 3 SELVA Study	Earnings call
2025-12-15	Palvella Therapeutics Conference Call to Discuss Topline Results from the Phase 2 TOIVA study	Earnings call
2025-11-12	Stifel 2025 Healthcare Conference	Conference
2025-11-11	Palvella’s Third Quarter 2025 Financial Results and Corporate Update Conference Call	Earnings call
2025-11-05	Palvella Therapeutics Conference Call to Discuss New Product Candidate QTORIN™ Pitavastatin for Disseminated Superficial Actinic Porokeratosis	Conference
2025-09-24	Palvella Therapeutics Conference Call to Discuss Expansion of QTORIN™ Rapamycin Pipeline to Include Clinically Significant Angiokeratomas	Conference

Source: https://ir.palvellatx.com/

Key facts CIK 1583648 CUSIP 697947109 13F (30d) 171 filings 168 filers Visit website Investor relations